297 related articles for article (PubMed ID: 24584067)
1. Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy.
Fu JJ; Kong WJ; Jiang D; Pan XC; Wei L
Antivir Ther; 2014; 19(7):661-8. PubMed ID: 24584067
[TBL] [Abstract][Full Text] [Related]
2. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
3. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
Nicot F; Alric L; Barange K; Métivier S; Dramard JM; Combis JM; Castan B; Meurisse JJ; Payen JL; Garipuy D; Desmorat H; Peron JM; Thebault S; Morin T; Renou C; Barel P; Guerin B; Imbert Y; Sire S; Sauné K; Chatelut E; Izopet J
J Med Virol; 2011 Mar; 83(3):437-44. PubMed ID: 21264864
[TBL] [Abstract][Full Text] [Related]
4. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2009 Mar; 81(3):452-8. PubMed ID: 19152407
[TBL] [Abstract][Full Text] [Related]
5. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.
Nakagawa M; Sakamoto N; Ueyama M; Mogushi K; Nagaie S; Itsui Y; Azuma S; Kakinuma S; Tanaka H; Enomoto N; Watanabe M
J Gastroenterol; 2010 Jun; 45(6):656-65. PubMed ID: 20112032
[TBL] [Abstract][Full Text] [Related]
7. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
[TBL] [Abstract][Full Text] [Related]
8. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
9. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P
Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092
[TBL] [Abstract][Full Text] [Related]
10. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
[TBL] [Abstract][Full Text] [Related]
12. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.
Kurosaki M; Sakamoto N; Iwasaki M; Sakamoto M; Suzuki Y; Hiramatsu N; Sugauchi F; Tamori A; Nakagawa M; Izumi N
J Med Virol; 2011 Mar; 83(3):445-52. PubMed ID: 21264865
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
[TBL] [Abstract][Full Text] [Related]
14. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
[TBL] [Abstract][Full Text] [Related]
16. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.
El-Shamy A; Nagano-Fujii M; Sasase N; Imoto S; Kim SR; Hotta H
Hepatology; 2008 Jul; 48(1):38-47. PubMed ID: 18537193
[TBL] [Abstract][Full Text] [Related]
17. Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.
Vermehren A; Welsch C; Elsler U; Vermehren J; Herrmann E; Sarrazin C; von Wagner M; Susser S; Hofmann WP; Kronenberger B; Zeuzem S; Mihm U
Antivir Ther; 2013; 18(6):803-11. PubMed ID: 23824381
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
[TBL] [Abstract][Full Text] [Related]
19. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
20. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
